Table 1 Demographic and clinical characteristics of the groups.
Demographic and clinical characteristics | HCT recipients (n = 32) | Patients with Hematological Malignancy (n = 465) | Patients without cancer (n = 497) | p value |
|---|---|---|---|---|
Gender | ||||
Male,n (%) | 25 (78.1%) | 250 (53.8%) | 269 (54.1%) | 0.03a |
Female, n (%) | 7 (21.9%) | 215 (46.2%) | 228 (45.9%) | |
Median age (years) | 56,5 (19–74) | 57 (18–93) | 55 (19–87) | 0.3 |
Comorbidity, n (%) | ||||
Diabetes Mellitus | 7 (21.9%) | 111 (23.9%) | 114 (22.9%) | 0.9 |
Hypertension | 18 (56.3%) | 201 (43.2%) | 200 (40.2%) | 0.2 |
Cardiovascular diseases | 5 (15.6%) | 69 (14.8%) | 63 (12.7%) | 0.6 |
Respiratory system diseases | 10 (31.3%) | 86 (18.5%) | 86 (17.3%) | 0.1 |
Additional Treatment, n (%) | ||||
Favipiravir | 12 (37.5%) | 131 (28.2%) | 128 (25.8%) | 0.3 |
Oseltamivir | 12 (37.5%) | 209 (44.9%) | 222 (44.7%) | 0.7 |
Lopinavir/ritonavir | 2 (6.3%) | 23 (4.9%) | 12 (2.4%) | 0.1 |
Hydroxychloroquine | 24 (75%) | 336 (72.3%) | 352 (70.8%) | 0.8 |
High dose vitamin C | 8 (25%) | 81 (17.4%) | 69 (13.9%) | 0.1 |
